|Bid||110.49 x 1800|
|Ask||111.10 x 1100|
|Day's Range||109.91 - 110.69|
|52 Week Range||88.00 - 119.44|
|Beta (5Y Monthly)||0.85|
|PE Ratio (TTM)||27.22|
|Earnings Date||Aug 03, 2020 - Aug 07, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||96.22|
An earnings release is available on the Company's website. Today, you will hear from China Biologic's Chairman and CEO, Mr. Joseph Chow, who will start off the call with a review of the Company's basic operating results and report recent developments for the Company. China Biologic's CFO, Mr. Ming Yang, will be available during the Q&A session following the prepared remarks.
China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today declared that Xinjiang Deyuan Bioengineering Co., Ltd. ("Xinjiang Deyuan"), China Biologic's source plasma supplier and cooperation partner, has materially breached its strategic cooperation with China Biologic by entering into plasma supply arrangements with Southern Shuanglin Bio-Pharmacy Co., Ltd. ("Shuanglin"), and that China Biologic will take all necessary measures to protect its rights.
China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited financial results for the first quarter of 2020.
China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release its first quarter 2020 financial results on Wednesday, May 20, 2020 after the market closes.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the fourth quarter and fiscal year of 2019.
China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release its fourth quarter and fiscal year 2019 financial results on Thursday, March 12, 2020 after the market closes.
Ah, diversification.It's a word you used to hear a lot about when it came to building a strong portfolio. But the thing is, trends change and all sorts of stories get written about income and/or growth being the bedrock of portfolios.In the height of the dotcom boom, brokers were telling their clients that growth was the new income and that those stupid income stocks were an anchor on their portfolio. Now, tech, e-commerce, and cannabis rule the day. But you need more than just those headline sectors in your portfolio.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThat's where mid-cap stocks come in. They are well suited for moderate growth markets like we're in now, because they can show more growth than lumbering large-cap stocks. They also offer more safety than small-caps. * The 8 Biggest Investing Surprises of 2019 These are 'Goldilocks' stocks that are worth a place in your portfolio. Below are seven ideal mid-cap stocks for a diverse portfolio. And they're all A-rated in my Portfolio Grader.Source: Shutterstock Avon Products (NYSE:AVP) may not be a name you thought you would see in this article, but it is back from oblivion and has actually posted some encouraging numbers in recent years.It's certainly a shadow of its former self, but it has retooled and shifted away from its U.S. base into developing markets where access to health and beauty products is more of a challenge.This was part of its allure in the U.S., when more of America was rural and getting a decent selection of beauty products was hard to come by on a regular basis. It was the same concept as the Sears catalog - it brought the store to you, but it involved having a real-life professional show you how to use the products - a makeup counter in your own home.This strategy has been working. And the cosmetics industry is predicted to boom in coming years.The stock is up a whopping 231% in the past year, so there are a lot of believers. In its latest quarter, profits were up but revenue missed slightly.Source: Casimiro PT / Shutterstock.com Carlyle Group (NYSE:CG) is essentially a private equity firm. Before (and after) it went public, it was the place where the Saudi royal family, the Bush family and other old money groups put some of their money in to diversify their portfolios beyond stocks and bonds.It was a very exclusive club. But then it opened up and started to wade into the water with other private equity firms. Now it owns real estate, buys into companies as turnaround plays, offers financing, etc.CG still a quiet company that has a very good track record. And even after running up 95% in the past year, the stock is only trading at a trailing PE under 11 and still delivers a solid 4.4% dividend. * 7 Biotech Stocks to Buy and Hold in 2020 There are certainly bigger names in this game, but CG's client list makes them a very interesting choice if you want to dip your toe into the growing private equity sector.Source: Shutterstock China Biologic Products (NASDAQ:CBPO) has been on my radar for many years. So it wasn't a surprise when a consortium came in and bought the company for $4 billion.When it started, CBPO was a solid medical company that focused on the boring end of drug development - plasma-based biopharmaceutical products for immune system disorders, epidemic diseases, and disaster relief medicines.Basically, it was making front line drugs for a developing economy. In China, that's a lot of business potential. And CBPO was one of the favorites of the government in the space.That means it gets the research grants and orders from the government. As a result, it went from a penny stock to a mid-cap stock literally overnight.It still has plenty of growth left in it, because these are precisely the kind of medical companies that China wants to build.Source: IgorGolovniov / Shutterstock.com ManTech International (NASDAQ:MANT) is an IT and technical services firm that works primarily in the defense sector. This is a very good place to be now.As we modernize the theater of war, it takes an extreme amount of technical support. Think about a networked battlefield with soldiers with heads-up display relaying information to other soldiers, equipment that locate where shots are coming from and calculate countermeasures, drones offering up images of potential combatants and non-combatants - all in real time.And then you have secure communications for covert operations and systems for intelligence services. This is all where MANT makes it business.The defense sector and intel services are very focused on electronic warfare. Money was put into the budget for a new space force as well. You can be sure that MANT is in the middle of all these new contracts. * 7 Energy Stocks That Are Still Worth Buying In 2020 The stock is up nearly 47% this year, yet it still trades at a trailing PE of 30. This is a good time to be a secure tech provider for defense and intel agencies.Source: Shutterstock Aqua America (NYSE:WTR) is one of the leading water companies east of the Rockies. It operates in Ohio, Texas, Illinois, North Carolina, Virginia, New Jersey and Indiana.Basically, as municipalities struggle to keep up to date on their water systems, they turn to companies like WTR to do it for them. Many older towns have outdated systems that need to be upgraded to current standards, pipes and pumps need to be replaced, and wastewater systems upgraded.WTR has the advantage of economies of scale and focused expertise. It has everything it needs on hand and do much of the work and maintenance cheaper than the towns can do it.It's a good business that works out for everyone. Residents get a value for their tax dollars and reliable drinking water, and companies gets long-term contracts.The stock is richly valued here, but the expectation is that WTR is in a growth phase now, so that shouldn't be an issue for long. Also, it has a rock-solid 2% dividend that adds to its allure.Source: madamF / Shutterstock.com Vipshop Holdings (NYSE:VIPS) is a Chinese e-commerce fashion retailer. Think of it as a Chinese version of Macy's (NYSE:M), but without the challenges of brick and mortar stores, or the loss of its brand power to emerging brands.VIPS is the emerging brand and it has a variety of products at all price points. In this way, it's also like a Chinese Amazon (NASDAQ:AMZN) of fashion for women, men and children.VIPS has come a long way in its 11 years. It has an $8 billion market cap now and the stock is up 163% in the past year. Remember, the U.S.-China trade war has been going on 18 months. * 7 Exciting Biotech Stocks to Buy Now The trade war has likely helped VIPS since it wasn't raising prices because of U.S. imports. It likely built an even bigger footprint for itself moving forward since it gained customers over that time. And now that the Chinese economy is on the mend, that means even more growth.Source: Shutterstock Kinross Gold (NYSE:KGC) is one of the bigger gold and silver mining players in the world. It's headquartered in Toronto, Canada but has mines all over the world, generally buying up smaller mines and adding them to its family.While gold may seem a bit antiquated an investment, the fact is, a good gold company is always a good hedge. When the markets are in turmoil or inflation starts to rise, gold rises in demand.And countries around the world still stockpile gold when they see market troubles.Also, silver is an industrial metal as well as a precious one. It's a crucial metal in a lot of high-performance electronics, so demand for silver can grow as demand for electronics expands.Miners don't follow the price of gold directly; they usually underperform when gold is weak and outperform when gold prices are strong. For example, gold is up 14% year to date but KGC is up 40%. This is neither good or bad, but it's good to know if you haven't owned a mining stock before.Again, this is a good hedge at a good time. It shouldn't be a major holding.Louis Navellier had an unconventional start, as a grad student who accidentally built a market-beating stock system -- with returns rivaling even Warren Buffett. In his latest feat, Louis discovered the "Master Key" to profiting from the biggest tech revolution of this (or any) generation. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 8 Biggest Investing Surprises of 2019 * 7 Impressive Stocks to Buy Over $250 * 4 Small-Cap Energy Stocks Ready to Explode The post 7 Ideal Mid-Cap Stocks for a Diverse Portfolio appeared first on InvestorPlace.
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of June. At Insider Monkey, we follow nearly 750 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]
Over the past 12 months, the Nasdaq Biotech Index (NBI) has kept up with the broader market, slightly outpacing the S&P 500, until the last few months.Certainly 2019 has been a bumpy ride. But it looks like the sector, especially thank to its larger firms, is finally hitting its stride. The index is rising and a growing number of mergers over the past couple years are starting to pay off.There are some amazing new technologies that are finally gaining traction on the medication side, which includes a long journey through U.S. Food and Drug Administration trials. It usually takes about 10 years and costs around $2 billion to get a drug through trials these days.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThat's a lot of commitment. And during that time, you need to develop a strong pipeline for future growth. * 7 Entertainment Stocks to Buy to Escape Holiday Blues At Growth Investor, we are focused on pure biotech stocks, not big pharma. These seven big biotech companies are driving cutting-edge therapies. These names are either currently thriving or well positioned for buyouts that would come with big premiums. Biotech Stocks to Buy: Galapagos (GLPG)Source: Shutterstock Galapagos (NASDAQ:GLPG) is a perfect example of the new wave in biotech. It uses adenoviruses -- viruses that usually cause respiratory illnesses -- to introduce human gene sequences to help or prevent certain proteins from multiplying.The formations of proteins play a critical role in a number of diseases, including cancer. They are also key in autoimmune diseases. And GLPG focuses on the latter.It has four drugs in clinical trials currently, and two of those are in Phase 3 trials. That is encouraging, since it is usually moving into Phase 3 trials where many drugs fall short.The stock is up a whopping 94% this year as trial results are driving price, yet its trailing price-to-earnings ratio is 38. It has a $12 billion market capitalization, so it's well funded. China Biologic Products (CBPO)Source: Shutterstock China Biologic Products (NASDAQ:CBPO) is one of China's leading biotech companies. Its work isn't fancy, but it's functional. And in a population of 1.4 billion people, high-quality drugs represent a huge step forward.China is very focused on developing its pharmaceutical and healthcare industry instead of relying on the U.S or Europe to sell it medicines. But this is a huge undertaking to start from nearly scratch.CBPO is one of the first to do it. It's not making cutting-edge drugs and doing breakthrough research -- it's focused on plasma-based biopharmaceutical products. These are fundamental for treatment of immune system disorders, epidemic diseases and disaster relief. * 10 Cheap Stocks to Buy Under $10 It gained a lot of attention last year when a consortium offered nearly $4 billion for the company. Its current market cap is $4.5 billion and the stock is up 54% year-to-date. That's the kind of momentum I like to see at Growth Investor, and there's still plenty of headroom here. Arrowhead Pharmaceuticals (ARWR)Source: Shutterstock Arrowhead Pharmaceuticals (NASDAQ:ARWR) works on novel drugs for intractable diseases. And that about sums up its focus.Right now, it has nine drugs in trials. Two of them are in Phase 3. One is for liver disease and the other for Hepatitis B. Most of its other drugs are focused on diseases affecting the liver. It also has one in trial for lung cancer and another for renal cell carcinoma.It is focused on using RNAi, or RNA interference, to prevent cells from expressing a specific gene, usually a gene linked to a disease. RNAi has been around for a long time, and ARWR has been around since 1989. But it's now coming into its own, as technologies have grown up around it.The stock is up a staggering 432% year-to-date, due to its own work and the interest that big pharma is now taking in the sector. With a $6.3 billion market cap, it would be an easy buy for a big firm looking to acquire a solid pipeline of RNAi drugs. Acadia Pharmaceuticals (ACAD)Source: Shutterstock Acadia Pharmaceuticals (NASDAQ:ACAD) focuses on central nervous system disorders. These range from schizophrenia to Parkinson's to major depressive disorder.It actually has a drug in the market. In 2016 Nuplazid was launched to help manage the hallucinations and disorientation sometimes experienced by Parkinson's patients. Second-quarter sales were $83 million, up 46% from the same quarter a year ago. That's more than $300 million a year, and growing.It has another drug that is wrapping up Phase 3 trials and is targeted at dementia-related psychosis. Yet another drug is halfway through Phase 3 trials focused on providing an adjunctive therapy for major depressive disorder.This firm isn't just about the future, it's succeeding in the market right now. And in a unique niche, no less. This niche will continue to grow as boomers age, so demographics are also on its side. That's the kind of growth potential I demand from stocks in any industry. * 9 Tantalizing Dividend Stocks for 2020 ACAD stock is up 182% year-to-date and with a $7 billion market cap, it's still the early days. Spark Therapeutics (ONCE)Source: Shutterstock Spark Therapeutics (NASDAQ:ONCE) is a gene therapy company that focuses on genetic diseases including blindness, hemophilia and neurodegenerative conditions.These can be good areas for a relatively young gene company to plant its flag, because they aren't usually filled with as much competition. That also means that during drug trials, its efficacies don't have to meet as high standards.ONCE just launched its first drug this year, Luxturna, for inherited retinal dystrophy, which ultimately leads to blindness. Sales and results have been positive. The company also has a licensing and development deal with Pfizer (NYSE:PFE) for a drug targeting hemophilia. And Novartis (NYSE:NVS) has control of European marketing for Luxturna.The stock is up 184% year-to-date and has a bright future if it can keep delivering. Zai Lab (ZLAB)Source: Shutterstock Zai Lab (NASDAQ:ZLAB) is a Chinese biotech that launched in 2014. But today, it has a $2.6 billion market cap. That's some pretty fast growth.Part of the reason is that Incyte Pharmaceuticals (NASDAQ:INCY), maker of the rheumatoid arthritis drug Jakafi, has become an investor. This partnership allows INCY to market its drug in China and gives ZLAB access to the U.S. market. At Growth Investor, we invest with an eye on macroeconomic trends, and these are the two markets exhibiting the strongest growth.Their product lines overlap as well, which has some strategic advantages. Both have products in autoimmune diseases, and ZLAB also is doing work in cancer and infectious diseases.ZLAB has 16 drugs in Phase 3 trials, with one, Optune, ready for market in Hong Kong. Its massive pipeline is especially attractive for a firm like INCY when looking at marketing some of these in the U.S. market. * 7 Top Stocks to Buy for 2020 The stock is up 73% year-to-date and could be a sleeping giant, if all unfolds according to plan. Natera (NTRA)Source: Shutterstock Natera (NASDAQ:NTRA) isn't a typical biotech in the sense that it develops drugs.Its niche is genetic testing. While you may think that begins and ends with prenatal testing for hereditary disorders and the like, the fact is, that's just the beginning.It can run testing on cancers so that oncologists can get an exact description of the cancer. Today, there are gene therapies and immuno-oncology therapies that can be used to help certain cancer patients. And that list is growing. Also, recurrence monitoring and treatment monitoring are much more targeted and accurate.Also, genetic testing can help make sure that transplants are more successful. For insurers and hospitals (as well as patients of course), a clean transplant means no issues with tissue rejection, infection or longer hospital stays.It might not have a sexy silver bullet in this sector, but it does have a great reputation.The stock is up 155% year-to-date. And given the lack of drama in the stock, its big growth could keep on going as long as the population continues to gray.All this gives you an idea of why these stocks rate so highly in my Portfolio Grader tool. And I've got more where that came from. There's a bigger, deeper tech trend going on that I'm even more excited about. 'The Mother of All Technologies'Up until now, technologies have certainly made our lives easier and more efficient … but with a lot of room for human error. People trip over cords, spill their coffee and get tired.Artificial intelligence does not.If that sounds futuristic, well then, the future is already here. If you use apps like Netflix (NASDAQ:NFLX), TurboTax, QuickBooks, Zillow (NASDAQ:Z) or even an email spam filter, then AI is already helping your day run more smoothly. And as scientists find even more applications for artificial intelligence -- from healthcare to retail to self-driving cars -- it's incredible to imagine how much data will be involved.To create AI programs in the first place, tech companies must collect vast amounts of data on human decisions. Data is what powers every AI system.So any one company that can help with customers' data issues is the one company that's most worth investing in.You don't need to be an expert to take part. I'll tell you everything you need to know, as well as my "buy" recommendation, in Growth Investor. My No. 1 stock for the AI trend is still under my buy limit price -- so you'll want to sign up now. Get in while it's still cheap.Click here for a free briefing on this groundbreaking innovation.Louis Navellier had an unconventional start, as a grad student who accidentally built a market-beating stock system -- with returns rivaling even Warren Buffett. In his latest feat, Louis discovered the "Master Key" to profiting from the biggest tech revolution of this (or any) generation. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Things to Watch for into 2020 for Safer Income & Growth * 7 Entertainment Stocks to Buy to Escape Holiday Blues * 5 "Strong Buy" Biotech Stocks With More Than 80% Upside The post 7 Exciting Biotech Stocks to Buy Now appeared first on InvestorPlace.
BEIJING, Nov. 13, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited financial results for the third quarter of 2019.
BEIJING , Nov. 4, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical ...
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 20% in 2019 (through September 30th). Conversely, hedge […]
BEIJING, Oct. 17, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the special committee (the "Special Committee") of the Company's board of directors (the "Board") has retained Duff & Phelps, LLC and Duff & Phelps Securities, LLC as its financial advisor and Davis Polk & Wardwell LLP as its legal counsel in connection with its review and evaluation of the previously announced preliminary non-binding going private proposal from Beachhead Holdings Limited, CITIC Capital China Partners IV, L.P., PW Medtech Group Limited, Parfield International Ltd., HH Sum-XXII Holdings Limited and V-Sciences Investments Pte. Ltd (the "Proposal").
BEIJING, Sept. 24, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its board of directors (the "Board") has formed a special committee (the "Special Committee") to review and evaluate the previously announced preliminary non-binding "going private" proposal (the "Proposal") that the Board received on September 18, 2019 from Beachhead Holdings Limited, CITIC Capital China Partners IV, L.P., PW Medtech Group Limited, Parfield International Ltd., HH Sum-XXII Holdings Limited and V-Sciences Investments Pte. Ltd. The Special Committee is composed of Mr. Sean Shao, Dr. Yungang Lu and Mr. Qi Ning, who are independent directors of the Company and are unaffiliated with the Proposal.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 19.) 10X Genomics Inc (NASDAQ: TXG ) (listed its ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 18) 10X Genomics Inc (NASDAQ: TXG ) (listed its shares ...
BEIJING, Sept. 18, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its board of directors (the "Board") has received a preliminary non-binding proposal letter, dated September 18, 2019, from Beachhead Holdings Limited, CITIC Capital China Partners IV, L.P., PW Medtech Group Limited, Parfield International Ltd., HH Sum-XXII Holdings Limited and V-Sciences Investments Pte. Ltd (collectively, the "Buyer Group"), proposing to acquire all of the outstanding ordinary shares of the Company not already owned by the Buyer Group for US$120 per share in cash in a "going private" transaction (the "Transaction").
NEW YORK, NY / ACCESSWIRE / August 6, 2019 / China Biologic Products Holdings, Inc. (NASDAQ: CBPO ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August ...
--2Q19 Total Sales Up 12.7% YoY in USD terms, or 20.4% YoY in RMB terms; Net Income Up 45.5% YoY to $41.6 Million ; Non-GAAP Adjusted Net Income Up 29.1% YoY in RMB terms -- --1H19 Total Sales Up 14.0% ...